PATH | VRL
Menu

An Extended Cost-Effectiveness Analysis of Publicly Financed HPV Vaccination to Prevent Cervical Cancer in China

This article, published in Vaccine, reports on a study to evaluate the cost-effectiveness of human papillomavirus (HPV) vaccination to prevent cervical cancer in China. The authors found that HPV is cost-effective across all income groups when the cost is less than US$50 per vaccinated girl. Compared to screening alone, adding preadolescent HPV vaccination followed by cervical cancer screening in adulthood could reduce cancer by 44 percent across all income groups, while providing relatively higher financial protection to the poorest women.

Author: Levin CE, Sharma M, Olson Z, et al.

Published: 2015

» Visit web page (English)

(Located at www.sciencedirect.com)

Citation: Levin CE, Sharma M, Olson Z, et al. An Extended Cost-Effectiveness Analysis of Publicly Financed HPV Vaccination to Prevent Cervical Cancer in China. Vaccine. 2015;33(24):2830-2841.

Resource types: Peer-reviewed journal

Diseases/vaccines: Human papillomavirus (HPV)

Topics: Immunization financing, Disease/vaccine specific information

Regions: Asia